0000000000174763

AUTHOR

Javed Khan

showing 4 related works from this author

The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.

2014

The Ewing sarcoma family of tumors (EFT) is a group of highly malignant small round blue cell tumors occurring in children and young adults. We report here the largest genomic survey to date of 101 EFT (65 tumors and 36 cell lines). Using a combination of whole genome sequencing and targeted sequencing approaches, we discover that EFT has a very low mutational burden (0.15 mutations/Mb) but frequent deleterious mutations in the cohesin complex subunit STAG2 (21.5% tumors, 44.4% cell lines), homozygous deletion of CDKN2A (13.8% and 50%) and mutations of TP53 (6.2% and 71.9%). We additionally note an increased prevalence of the BRCA2 K3326X polymorphism in EFT patient samples (7.3%) compared …

MaleCancer ResearchCell Cycle Proteinsmedicine.disease_causeFusion geneCDKN2AMedicine and Health Sciences2.1 Biological and endogenous factorsAetiologyChildGenetics (clinical)CancerPediatricMutationTissue microarrayTumorGenomeSarcomasHigh-Throughput Nucleotide SequencingAntigens NuclearSarcomaNeoplasm ProteinsOncologyChild PreschoolFemaleSarcomaResearch ArticleBiotechnologyHumanAdultPediatric Research Initiativelcsh:QH426-470Cohesin complexAdolescentPediatric CancerEwing SarcomaSarcoma EwingBiologyDisease-Free SurvivalFrameshift mutationCell LineGermline mutationRare DiseasesCell Line TumorEwingCancer GeneticsmedicineGeneticsHumansNuclearGenetic TestingAntigensPreschoolMolecular BiologyEcology Evolution Behavior and SystematicsGenome HumanHuman GenomeBiology and Life SciencesCancers and NeoplasmsInfantmedicine.diseaselcsh:GeneticsOrphan DrugMutationCancer researchGene DeletionDevelopmental Biology
researchProduct

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

2012

Background: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. Methods: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. Results: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental a…

OncologyCancer Researchmedicine.medical_specialtyPathologyBiologyLoss of heterozygosityneuroblastomaNeuroblastomaInternal medicineINRGmedicineHumansClinical significancegenomic profileSurvival analysisRetrospective StudiesChromosome AberrationsOncogene ProteinsN-Myc Proto-Oncogene ProteinUnivariate analysisgenetic alterationsChromosomes Human Pair 11InfantNuclear ProteinsChromosomeGenetics and GenomicsPrognosismedicine.diseaseSurvival AnalysisOncologyGenetic markerGenomic ProfileChromosomes Human Pair 17British Journal of Cancer
researchProduct

Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma

2017

Given the paucity of druggable mutations in high-risk neuroblastoma (NB), we undertook chromatin-focused small interfering RNA and chemical screens to uncover epigenetic regulators critical for the differentiation block in high-risk NB. High-content Opera imaging identified 53 genes whose loss of expression led to a decrease in NB cell proliferation and 16 also induced differentiation. From these, the secondary chemical screen identified SETD8, the H4K20me1 methyltransferase, as a druggable NB target. Functional studies revealed that SETD8 ablation rescued the pro-apoptotic and cell-cycle arrest functions of p53 by decreasing p53K382me1, leading to activation of the p53 canonical pathway. I…

p530301 basic medicineCancer ResearchSmall interfering RNAMethyltransferaseCellular differentiationDruggabilityBiologyArticleEpigenesis GeneticNeuroblastoma03 medical and health sciences0302 clinical medicineNeuroblastomamedicineHumansEpigeneticsRNA Small InterferingGeneCell ProliferationsiRNA screenCell growthQuinazolineCell DifferentiationdifferentiationHistone-Lysine N-Methyltransferasemedicine.diseaseSETD8030104 developmental biologyOncology030220 oncology & carcinogenesisQuinazolinesCancer researchdifferentiation; epigenetics; neuroblastoma; p53; SETD8; siRNA screen; Oncology; Cell Biology; Cancer ResearchTumor Suppressor Protein p53epigeneticHuman
researchProduct

An Effective Wireless Sensor Network Routing Protocol Based on Particle Swarm Optimization Algorithm

2022

Improving wireless communication and artificial intelligence technologies by using Internet of Things (Itoh) paradigm has been contributed in developing a wide range of different applications. However, the exponential growth of smart phones and Internet of Things (IoT) devices in wireless sensor networks (WSNs) is becoming an emerging challenge that adds some limitations on Quality of Service (QoS) requirements. End-to-end latency, energy consumption, and packet loss during transmission are the main QoS requirements that could be affected by increasing the number of IoT applications connected through WSNs. To address these limitations, an effective routing protocol needs to be designed for …

Article SubjectComputer Networks and CommunicationsComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSElectrical and Electronic EngineeringVDP::Teknologi: 500::Informasjons- og kommunikasjonsteknologi: 550Information Systems
researchProduct